Literature DB >> 22795368

Antipsychotics, dopamine D₂ receptor occupancy and clinical improvement in schizophrenia: a meta-analysis.

Zeynep Yilmaz1, Clement C Zai, Rudi Hwang, Steve Mann, Tamara Arenovich, Gary Remington, Zafiris J Daskalakis.   

Abstract

OBJECTIVE: Treatment of schizophrenia (SCZ) was revolutionized with the development of the antipsychotic medications. Although imaging studies have linked antipsychotic D₂ receptor occupancy and clinical response in SCZ, heterogeneity between cohorts and methods has made it challenging to generalize findings across studies. The main objective of this meta-analysis was to analyze the relationship between in vivo estimation of typical and atypical antipsychotic D₂ receptor occupancy and treatment response in SCZ.
METHODS: Using the keywords "dopamine D₂ receptor occupancy," "schizophrenia," "PET/SPECT" and "antipsychotics," and further refining our search to journal articles with information on % striatal D₂ occupancy and % change in clinical symptoms as indexed by either the BPRS or the PANSS, our final analysis consisted of 16 imaging studies (20 cohorts; N=206).
RESULTS: The first step of the meta-analysis confirmed the positive relationship between antipsychotic medication and clinical improvement in SCZ (ES=1.36; 95% CI: 1.13-1.60). The second step of our analysis revealed that when D₂ occupancy was limited to less than 80% in order to control for the appearance of extrapyramidal symptoms, high D₂ occupancy was correlated with reduction in clinical scores (r=0.4, p<0.001) for medications other than clozapine or quetiapine.
CONCLUSIONS: Our results suggest that D₂ occupancy is a contributing factor for the mechanism of antipsychotic effect in SCZ for some but not all antipsychotic medications.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22795368     DOI: 10.1016/j.schres.2012.06.027

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  24 in total

1.  Effects of the T-type calcium channel antagonist Z944 on paired associates learning and locomotor activity in rats treated with the NMDA receptor antagonist MK-801.

Authors:  Andrew J Roebuck; Wendie N Marks; Max C Liu; Nimra B Tahir; Nadine K Zabder; Terrance P Snutch; John G Howland
Journal:  Psychopharmacology (Berl)       Date:  2018-09-24       Impact factor: 4.530

Review 2.  Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia.

Authors:  Shinichiro Nakajima; Hiroyoshi Takeuchi; Eric Plitman; Gagan Fervaha; Philip Gerretsen; Fernando Caravaggio; Jun Ku Chung; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Schizophr Res       Date:  2015-02-13       Impact factor: 4.939

3.  Histamine H1 receptor occupancy by the new-generation antipsychotics olanzapine and quetiapine: a positron emission tomography study in healthy volunteers.

Authors:  Hirotoshi Sato; Chihiro Ito; Kotaro Hiraoka; Manabu Tashiro; Katsuhiko Shibuya; Yoshihito Funaki; Takeo Yoshikawa; Ren Iwata; Hiroo Matsuoka; Kazuhiko Yanai
Journal:  Psychopharmacology (Berl)       Date:  2015-07-07       Impact factor: 4.530

4.  Sex and laterality differences in parkinsonian impairment and transcranial ultrasound in never-treated schizophrenics and their first degree relatives in an Andean population.

Authors:  Danielle Kamis; Lee Stratton; María Calvó; Eduardo Padilla; Néstor Florenzano; Gonzalo Guerrero; Beatriz Molina Rangeon; Juan Molina; Gabriel A de Erausquin
Journal:  Schizophr Res       Date:  2015-02-27       Impact factor: 4.939

Review 5.  Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment.

Authors:  Masataka Wada; Yoshihiro Noda; Yusuke Iwata; Sakiko Tsugawa; Kazunari Yoshida; Hideaki Tani; Yoji Hirano; Shinsuke Koike; Daiki Sasabayashi; Haruyuki Katayama; Eric Plitman; Kazutaka Ohi; Fumihiko Ueno; Fernando Caravaggio; Teruki Koizumi; Philip Gerretsen; Takefumi Suzuki; Hiroyuki Uchida; Daniel J Müller; Masaru Mimura; Gary Remington; Anthony A Grace; Ariel Graff-Guerrero; Shinichiro Nakajima
Journal:  Mol Psychiatry       Date:  2022-04-20       Impact factor: 15.992

6.  A preliminary genetic association study of GAD1 and GABAB receptor genes in patients with treatment-resistant schizophrenia.

Authors:  Atsuhiro Miyazawa; Nobuhisa Kanahara; Masanobu Kogure; Ikuo Otsuka; Satoshi Okazaki; Yoshinori Watanabe; Fumiaki Yamasaki; Yusuke Nakata; Yasunori Oda; Akitoyo Hishimoto; Masaomi Iyo
Journal:  Mol Biol Rep       Date:  2021-11-29       Impact factor: 2.316

7.  Striatal and Thalamic Auditory Response During Deep Brain Stimulation for Essential Tremor: Implications for Psychosis.

Authors:  Judith M Gault; John A Thompson; Keeran Maharajh; Patrick Hosokawa; Karen E Stevens; Ann Olincy; Erin I Liedtke; Alex Ojemann; Steven Ojemann; Aviva Abosch
Journal:  Neuromodulation       Date:  2020-02-05

8.  A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse.

Authors:  Mark Abie Horowitz; Sameer Jauhar; Sridhar Natesan; Robin M Murray; David Taylor
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 7.348

9.  D-amphetamine and antipsychotic drug effects on latent inhibition in mice lacking dopamine D2 receptors.

Authors:  C Bay-Richter; M J O'Callaghan; N Mathur; C M P O'Tuathaigh; D M Heery; K C F Fone; J L Waddington; P M Moran
Journal:  Neuropsychopharmacology       Date:  2013-02-19       Impact factor: 7.853

Review 10.  Binding of clozapine to the GABAB receptor: clinical and structural insights.

Authors:  Pramod C Nair; Ross A McKinnon; John O Miners; Tarun Bastiampillai
Journal:  Mol Psychiatry       Date:  2020-03-13       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.